The study on vancomycin dosing during continuous venovenous haemofiltration (CVVH) in critically ill patients based on population pharmacokinetic modelling

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17012979

Enrollment

Unknown

Registered

2017-10-14

Start date

2018-01-01

Completion date

Unknown

Last updated

2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection

Interventions

Modeling group:Blood sampling

Validation group:Blood sampling

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >16 years, male or female; 2. Vancomycin is needed for anti-infective treatment (determined by attending physician); 3. Need to receive concomitant treatment with CVVH for =72h (the effective duration of CVVH within a day =16h).

Exclusion criteria

Exclusion criteria: 1. Patients with known hematological disease; 2. Patients who suffered uncontrolled mental disorders; 3. Patients who are pregnant; 4. Expected survival time less than the treatment cycle (at least 72h); 5. Patients with other factors that researcher considers unsuitable for inclusion.

Design outcomes

Primary

Measure	Time frame
Plasma concentration of vancomycin;	—

Countries

China

Contacts

Public ContactChao Zhang

Peking University Third Hospital

laural.zhang@yahoo.com+86 13718904426

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026